A practical reference on hGH fragment: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
=== Legal status === In the Netherlands, midazolam is a List II drug of the Opium Law. Midazolam is a Schedule IV drug under the Convention on Psychotropic Substances. In the United Kingdom, midazolam is a Schedule 3/Class C controlled drug. In the United States, midazolam (DEA number 2884) is on the Schedule IV list of the Controlled Substances Act as a non-narcotic agent with low potential for abuse.
On 7 April, Trump announced that the US and Iran had reached an agreement based on the 10-point proposal mediated by Pakistani prime minister Shehbaz Sharif and Field Marshal Asim Munir. The US, Israel, and Iran agreed to a two-week ceasefire, under which Iran would re-open the Strait of Hormuz. After the announcement, Iran's Lavan Island oil refinery and Sirri Island crude export facilities were struck; no party claimed responsibility. In response, Iran continued missile and drone strikes on Gulf Arab states. The refinery attack was later revealed to have been done secretly by the UAE.
Car buyers must pay for Additional Registration Fees (ARF) duties of either 100%, 140%, 180% or 220% of the vehicle's Open Market Value (OMV), and bid for a Singaporean Certificate of Entitlement (COE) (that varies twice a month in supply based on the number of car registrations and de-registrations), which allows the car to be driven on the road for maximum period of 10 years. Car prices are generally significantly higher in Singapore than in other English-speaking countries. As with most Commonwealth countries, vehicles on the road and people walking on the streets keep to the left (left-hand traffic). In 2025, Singapore started actively engaging in autonomous vehicle testing. In November 2025, the Land Transport Authority (LTA) approved WeRide and Grab to test 11 autonomous vehicles on two Punggol shuttle routes after initial tests in October, and aim for public passengers by early 2026. The Johor–Singapore Causeway (connecting Singapore with Johor Bahru, Malaysia) is the busiest international land border crossing in the world, whereby approximately 350,000 travellers cross the border checkpoints of both Woodlands Checkpoint and Sultan Iskandar Building daily (with an annual total of 128 million travellers). The Land Transport Authority (LTA) is responsible for all land transport-related infrastructure and operations in Singapore.
Sources: en.wikipedia.org
Four members of 2A peptides family are frequently used in life science research. They are P2A, E2A, F2A, and T2A. F2A is derived from foot-and-mouth disease virus 18; E2A is derived from equine rhinitis A virus; P2A is derived from porcine teschovirus-1 2A; T2A is derived from thosea asigna virus 2A. The following table shows the sequences of four members of 2A peptides. Adding the optional linker “GSG” (Gly-Ser-Gly) on the N-terminal of a 2A peptide greatly helps with efficiency. 2A peptides trigger the ribosome to skip peptide bond formation between the glycine (G) and proline (P) near the C-terminus of the 2A peptide, resulting in the peptide located upstream of the 2A peptide having extra amino acids appended to its C-terminus while the protein downstream the 2A peptide will have an extra proline on its N-terminus. The exact molecular mechanism of 2A-peptide-mediated cleavage is still unknown. However, it is believed to involve ribosomal "skipping" of glycyl-prolyl peptide bond formation rather than true proteolytic cleavage.
All actinides are radioactive and release energy upon radioactive decay; naturally occurring uranium and thorium, and synthetically produced plutonium are the most abundant actinides on Earth. These have been used in nuclear reactors, and uranium and plutonium are critical elements of nuclear weapons. Uranium and thorium also have diverse current or historical uses, and americium is used in the ionization chambers of most modern smoke detectors. Due to their long half-lives, only thorium and uranium are found on Earth and astrophysically in substantial quantities. The radioactive decay of uranium produces transient amounts of actinium and protactinium, and atoms of neptunium and plutonium are occasionally produced from transmutation reactions in uranium ores. The other actinides are purely synthetic elements. Nuclear weapons tests have released at least six actinides heavier than plutonium into the environment; analysis of debris from the 1952 first test of a hydrogen bomb showed the presence of americium, curium, berkelium, californium, and the discovery of einsteinium and fermium. In presentations of the periodic table, the f-block elements are customarily shown as two additional rows below the main body of the table. This convention is entirely a matter of aesthetics and formatting practicality; a rarely used wide-formatted periodic table inserts the 4f and 5f series in their proper places, as parts of the table's sixth and seventh rows (periods).
=== A10AE Insulins and analogues for injection, long-acting === A10AE01 Insulin (human) A10AE02 Insulin (beef) A10AE03 Insulin (pork) A10AE04 Insulin glargine A10AE05 Insulin detemir A10AE06 Insulin degludec A10AE07 Insulin icodec A10AE30 Combinations A10AE54 Insulin glargine and lixisenatide A10AE56 Insulin degludec and liraglutide A10AE57 Insulin icodec and semaglutide
Some people misinterpreted Rice's memoirs as admitting to Georgia's responsibility for starting the war. On 5 August 2012, a new documentary "A Lost Day" (Russian: "Потерянный день") was released on YouTube. The authors of the documentary were unknown. Several high-ranking military officials were featured. Yuri Baluyevsky, former Chief of the General Staff of Russia said that President Dmitry Medvedev didn't want to make a decision to go to war for some time. Baluyevsky said that it was Putin that had ordered to "retaliate" militarily against Georgia "after the first tensions", however "high-level officials" in Moscow had the fear of responsibility "until a kick in one place from Vladimir Vladimirovich in Beijing followed." Baluyevsky said after President Putin had decided to wage the war against Georgia prior to the May 2008 inauguration of Dmitry Medvedev as president of Russia, a military action was planned and explicit orders were issued in advance before August 2008. Russian researcher Andrey Illarionov later commented on the movie that the movie and the remarks of Putin confirmed the date of issue of the order by Medvedev to the Russian military to cross the border into Georgia was the night of 4-5 August. Russian Generals said in the movie that the plan intended that Russian troops would reach Tskhinvali on the morning of 8 August, but they actually reached Tskhinvali on the morning of 10 August. Illarionov attributed this delay of the Russian troops to the Georgian resistance.
Sources: en.wikipedia.org
Slurry ice is a phase changing refrigerant made up of millions of ice "micro-crystals" (typically 0.1 to 1 mm in diameter) formed and suspended within a solution of water and a freezing point depressant. Some compounds used in the field are salt, ethylene glycol, propylene glycol, alcohols like isobutyl and ethanol, and sugars like sucrose and glucose. Slurry ice has greater heat absorption compared to single phase refrigerants like brine, because the melting enthalpy (latent heat) of the ice is also used.
== Industrial uses == Micrococci, like many other representatives of the Actinobacteria, can be catabolically versatile, with the ability to utilize a wide range of unusual substrates, such as pyridine, herbicides, chlorinated biphenyls, and oil. They are likely involved in detoxification or biodegradation of many other environmental pollutants. Other Micrococcus isolates produce various useful products, such as long-chain (C21-C34) aliphatic hydrocarbons for lubricating oils.
=== Basal rate determination === Basal insulin requirements will vary between individuals and periods of the day. The basal rate for a particular time period is determined by fasting while periodically evaluating the blood sugar level. Neither food nor bolus insulin must be taken for 4 hours before or during the evaluation period. If the blood sugar level changes dramatically during evaluation, then the basal rate can be adjusted to increase or decrease insulin delivery to keep the blood sugar level approximately steady. For instance, to determine an individual's morning basal requirement, they must skip breakfast. On waking, they would test their blood glucose level periodically until lunch. Changes in blood glucose level are compensated with adjustments in the morning basal rate. The process is repeated over several days, varying the fasting period, until a 24-hour basal profile has been built up which keeps fasting blood sugar levels relatively steady. Once the basal rate is matched to the fasting basal insulin need, the pump user will then gain the flexibility to skip or postpone meals such as sleeping late on the weekends or working overtime on a weekday. Many factors can change insulin requirements and require an adjustment to the basal rate:
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.